Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone972-74-710-7259
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Profitability
Miscellaneous
Employees172
Next Earnings DateN/A
OptionableOptionable
Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?
Pluristem Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.90) by $0.10. View Pluristem Therapeutics' Earnings History.
What price target have analysts set for PSTI?
3 analysts have issued 12-month target prices for Pluristem Therapeutics' shares. Their forecasts range from $8.00 to $15.50. On average, they anticipate Pluristem Therapeutics' share price to reach $11.75 in the next twelve months. This suggests a possible upside of 266.0% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.
What is the consensus analysts' recommendation for Pluristem Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.
What are Wall Street analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (10/17/2019)
- 2. Maxim Group analysts commented, "Pluristem provided a shareholder update to highlight upcoming milestones. The company also completed an equity financing on 4/8 raising $21M. We estimate the company has ~$27M in cash on the balance sheet." (4/24/2019)
Has Pluristem Therapeutics been receiving favorable news coverage?
News articles about PSTI stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pluristem Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Pluristem Therapeutics.
Are investors shorting Pluristem Therapeutics?
Pluristem Therapeutics saw a decline in short interest in October. As of October 31st, there was short interest totalling 128,900 shares, a decline of 22.1% from the September 30th total of 165,400 shares. Based on an average daily volume of 54,800 shares, the short-interest ratio is presently 2.4 days. Currently, 0.9% of the company's shares are sold short. View Pluristem Therapeutics' Current Options Chain.
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include BioCryst Pharmaceuticals (BCRX), Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Solid Biosciences (SLDB), Aptose Biosciences (APTO), Windtree Therapeutics (WINT), Gamida Cell (GMDA), Novavax (NVAX), Nantkwest (NK), Fennec Pharmaceuticals (FENC), Erytech Pharma (ERYP), Acorda Therapeutics (ACOR) and Adaptimmune Therapeutics (ADAP).
What other stocks do shareholders of Pluristem Therapeutics own?
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Mr. Zami Aberman, Chairman & Co-CEO (Age 65)
- Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 48)
- Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 35)
- Mr. Boaz Leshem, VP Operations & Manufacturing (Age 59)
- Ms. Efrat Kaduri, Director of Bus., Investor and PR
Who are Pluristem Therapeutics' major shareholders?
Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.39%), Nikko Asset Management Americas Inc. (1.39%) and California Public Employees Retirement System (0.12%). Company insiders that own Pluristem Therapeutics stock include Mark Germain, Moria Kwiat and Yaky Yanay. View Institutional Ownership Trends for Pluristem Therapeutics.
Which institutional investors are selling Pluristem Therapeutics stock?
How do I buy shares of Pluristem Therapeutics?
Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of PSTI stock can currently be purchased for approximately $3.21.
How big of a company is Pluristem Therapeutics?
What is Pluristem Therapeutics' official website?
How can I contact Pluristem Therapeutics?
Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-7259 or via email at [email protected]
MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
